Body mass index trends and its impact of under and overweight on outcome among PLHIV on antiretroviral treatment in rural Tanzania: A prospective cohort study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
03
2023
accepted:
09
08
2023
medline:
24
8
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
epublish
Résumé
Increased body weight is an important risk factor for cardiovascular disease and is increasingly reported as a health problem in people living with HIV (PLHIV). There is limited data from rural sub-Saharan Africa, where malnutrition usually presents with both over- and undernutrition. We aimed to determine the prevalence and risk factors of underweight and overweight/obesity in PLHIV enrolled in a cohort in rural Tanzania before the introduction of integrase inhibitors. This nested study of the prospective Kilombero and Ulanga Antiretroviral Cohort included adults aged ≥19 years initiated on antiretroviral therapy between 01/2013 and 12/2018 with follow-up through 06/2019. Body Mass Index (BMI) was classified as underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2), or overweight/obese (≥25.0 kg/m2). Stratified piecewise linear mixed models were used to assess the association between baseline characteristics and follow-up BMI. Cox proportional hazard models were used to assess the association between time-updated BMI and death/loss to follow-up (LTFU). Among 2,129 patients, 22,027 BMI measurements (median 9 measurements: interquartile range 5-15) were analysed. At baseline, 398 (19%) patients were underweight and 356 (17%) were overweight/obese. The majority of patients were female (n = 1249; 59%), and aged 35-44 years (779; 37%). During the first 9 months, for every three additional months on antiretroviral therapy, BMI increased by 2% (95% confidence interval 1-2%, p<0.0001) among patients underweight at baseline and by 0.7% (0.5-0.6%, p<0.0001) among participants with normal BMI. Over a median of 20 months of follow-up, 107 (5%) patients died and 592 (28%) were LTFU. Being underweight was associated with >2 times the hazard of death/LTFU compared to participants with normal BMI. We found a double burden of malnutrition, with underweight being an independent predictor of mortality. Monitoring and measures to address both states of malnutrition among PLHIV should be integrated into routine HIV care.
Identifiants
pubmed: 37607169
doi: 10.1371/journal.pone.0290445
pii: PONE-D-23-06462
pmc: PMC10443839
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0290445Subventions
Organisme : Wellcome Trust
ID : 107768/Z/15/Z
Pays : United Kingdom
Organisme : PEPFAR
Pays : United States
Informations de copyright
Copyright: © 2023 Kalinjuma et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
I have read the journal’s policy and the author of this manuscript has the following competing interests: Emilio Letang is a full-time employee ViiV Healthcare since May 2021. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Other authors have declared that no competing interests exist.
Références
Swiss Med Wkly. 2017 Jul 11;147:w14485
pubmed: 28695551
PLoS One. 2023 Mar 24;18(3):e0283502
pubmed: 36961844
Arch Intern Med. 2007 Sep 10;167(16):1720-8
pubmed: 17846390
EClinicalMedicine. 2022 May 12;48:101412
pubmed: 35706487
Am J Epidemiol. 2010 Apr 15;171(8):924-31
pubmed: 20219765
Blood. 2006 Mar 1;107(5):1747-50
pubmed: 16189263
AIDS. 2019 Nov 1;33(13):2049-2059
pubmed: 31577571
PLoS One. 2017 Jul 18;12(7):e0180983
pubmed: 28719610
Virtual Mentor. 2010 Mar 01;12(3):202-6
pubmed: 23140869
Global Health. 2009 Sep 14;5:9
pubmed: 19751503
J Int AIDS Soc. 2020 Mar;23(3):e25460
pubmed: 32128998
Lancet. 2020 Jan 4;395(10217):65-74
pubmed: 31852602
Am J Clin Nutr. 2006 Jun;83(6):1387-94
pubmed: 16762951
Biometrics. 2010 Sep;66(3):891-6
pubmed: 19764951
Open Heart. 2015 Mar 20;2(1):e000174
pubmed: 25815207
AIDS Res Ther. 2016 Feb 25;13:12
pubmed: 26925155
BMC Med. 2014 Jul 29;12:125
pubmed: 25070128
N Engl J Med. 2019 Aug 29;381(9):816-826
pubmed: 31339676
N Engl J Med. 2019 Dec 19;381(25):2440-2450
pubmed: 31851800
J Int AIDS Soc. 2022 Apr;25(4):e25899
pubmed: 35419973
Stat Med. 2010 Feb 20;29(4):504-20
pubmed: 20013937
Nat Rev Endocrinol. 2020 Mar;16(3):177-189
pubmed: 32020062
Clin Infect Dis. 2020 Mar 17;70(7):1267-1274
pubmed: 31100116
AIDS. 2018 Jul 1;32 Suppl 1:S5-S20
pubmed: 29952786
J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):507-13
pubmed: 19730111
Int J Epidemiol. 2013 Dec;42(6):1754-71
pubmed: 24415610
Int J Methods Psychiatr Res. 2002;11(2):68-74
pubmed: 12459796
PLoS One. 2011;6(12):e28691
pubmed: 22220193
PLoS One. 2020 Aug 24;15(8):e0237720
pubmed: 32834011
Healthcare (Basel). 2020 Aug 24;8(3):
pubmed: 32846888
N Engl J Med. 2019 Aug 29;381(9):803-815
pubmed: 31339677
Clin Infect Dis. 2015 Jun 15;60(12):1852-9
pubmed: 25761868
Curr HIV/AIDS Rep. 2021 Apr;18(2):87-97
pubmed: 33606196
AIDS Res Treat. 2022 May 13;2022:2965325
pubmed: 35603131
PLoS One. 2012;7(10):e47761
pubmed: 23082211
BMC Infect Dis. 2021 Jan 4;21(1):1
pubmed: 33390160
Am J Clin Nutr. 2013 Jun;97(6):1278-87
pubmed: 23636235
Glob Health Action. 2014 Sep 29;7:25488
pubmed: 25280741
Lancet. 2011 Aug 27;378(9793):804-14
pubmed: 21872749
BMC Womens Health. 2022 Jun 21;22(1):246
pubmed: 35729541
Am J Epidemiol. 2021 Feb 1;190(2):251-264
pubmed: 33524120